Overview

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

Status:
Recruiting

Trial end date:
2020-05-20

Target enrollment:
0

Participant gender:
All

Summary

New Corona virus (COVID-19) has made a horrible situation for all of the countries. This disease is not only a health problem but also economy, culture and the whole entity of the countries is under attack by the virus. This disease seems to affect the body in two different pathology pathways. From one side virus can decrease activity of immune system in the blood stream and whole body and from other side it can attack the respiratory cells. Tissue biopsy shows that immune cells penetrate into the Lung tissue and we have accumulation and over activity of Immune cells in the lung. This inflammation in respiratory tract probably is the major cause of Cytokine storm and release of TNF-α and IL-6 into the blood. It seems that by three strategy disease can be treated. 1- By using systemic immune simulators. 2- By using topical anti-inflammatory drug in the respiratory system (Steroids or NSAIDs) 3- By inhibition of replication of the virus in the attacked cells.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Fasa University of Medical Sciences

Treatments:

Budesonide
Chloroquine
Formoterol Fumarate
Hydroxychloroquine
Levamisole
Lopinavir
Ritonavir

Criteria

Inclusion Criteria:

Definitely positive COVID-19 patients

Exclusion Criteria:

Patients with acute respiratory problems including patients with:

1. Spo2<60%

2. Severe respiratory distress

3. Heamodynamic instabilitty

4. Acid base disturbance

5. Severe Anemia Patients with severe hepatic diseases Patients with Nurvous system
diseases